GLPG1690

an autotaxin inhibitor; structure in first source

Also Known As:

2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo(1,2-a)pyridin-3-yl)methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile; GLPG-1690; ziritaxestat

Networked: 17 relevant articles (2 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - GLPG1690: 17
  - Pyrimidines: 510
    - GLPG1690: 17

Experts

1.	Fieuw, Ann: 4 articles (10/2019 - 01/2018)
2.	Heckmann, Bertrand: 3 articles (01/2020 - 11/2017)
3.	Desrivot, Julie: 3 articles (10/2019 - 01/2018)
4.	Fagard, Liesbeth: 3 articles (10/2019 - 01/2018)
5.	Helmer, Eric: 2 articles (01/2022 - 10/2019)
6.	Benesch, Matthew G K: 2 articles (02/2020 - 01/2020)
7.	Brindley, David N: 2 articles (02/2020 - 01/2020)
8.	Tang, Xiaoyun: 2 articles (02/2020 - 01/2020)
9.	Monjardet, Alain: 2 articles (01/2020 - 11/2017)
10.	Dupont, Sonia: 2 articles (10/2019 - 01/2018)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2020 - "Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer." 01/01/2020 - "In this work, we studied the effects of an ATX inhibitor, GLPG1690, which is in phase III clinical trials for idiopathic pulmonary fibrosis, on responses to radiotherapy and chemotherapy in a syngeneic orthotopic mouse model of breast cancer. "
2.	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/01/2023 - "The efficacy of the ATX/LPA signaling responses are abrogated more efficiently by tunnel-binding inhibitors, such as ziritaxestat (GLPG1690), compared with inhibitors that exclusively target the active site, as shown in primary lung fibroblasts and a murine model of radiation-induced pulmonary fibrosis. "
3.	Idiopathic Pulmonary Fibrosis 01/01/2023 - "Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials." 02/06/2020 - "After a decade of intense preclinical investigations, the first in-class autotaxin inhibitor, GLPG1690, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. " 01/01/2019 - "Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)." 01/01/2019 - "A third trial was conducted in patients with idiopathic pulmonary fibrosis administered 600 mg of GLPG1690 once daily for 12 weeks. " 01/01/2019 - "The aim of the current article was to describe the exposure-response relationship of GLPG1690 and further develop a rational basis to support dose selection for clinical trials in patients with idiopathic pulmonary fibrosis. "
4.	Neoplasms (Cancer) 01/01/2020 - "GLPG1690 also increased 4-hydroxynonenal-protein adducts in these tumors. " 01/01/2020 - "However, GLPG1690 decreased the uptake of 3'-deoxy-3'-[18F]-fluorothymidine by tumors and the percentage of Ki67-positive cells. " 01/01/2020 - "GLPG1690 combined with irradiation did not decrease tumor growth further compared with radiation alone. " 09/28/2023 - "An in vivo study showed that intraperitoneal injection of GLPG1690, an ATX inhibitor, suppressed tumor progression in a xenograft model. " 01/01/2020 - "GLPG1690 acted synergistically with doxorubicin to decrease tumor growth and the percentage of Ki67-positive cells. "
5.	Diffuse Scleroderma (Progressive Systemic Sclerosis) 01/01/2023 - "We undertook this study to explore the efficacy, safety, and tolerability of ziritaxestat, a selective autotaxin inhibitor, in patients with early diffuse cutaneous systemic sclerosis (dcSSc). " 01/01/2023 - "A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis."

Related Drugs and Biologics

1.	GLPG1690
2.	lysophosphatidic acid
3.	Chemokines
4.	Interleukin-9 (Interleukin 9)
5.	Macrophage Colony-Stimulating Factor
6.	Biomarkers (Surrogate Marker)
7.	Thiazoles
8.	Enzymes
9.	Doxorubicin (Adriamycin)
10.	Ribosomal DNA (rDNA)

Related Therapies and Procedures

1.	Radiotherapy
2.	Drug Therapy (Chemotherapy)
3.	Intraperitoneal Injections
4.	Aftercare (After-Treatment)